You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 9, September 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Otologic Effects of Interferon Beta Serine in Experimental Rhinovirus Colds

Steven J. Sperber, MD; William J. Doyle, PhD; Timothy P. McBride, MD; James V. Sorrentino, PhD; Donald K. Riker, PhD; Frederick G. Hayden, MD

Arch Otolaryngol Head Neck Surg. 1992;118(9):933-936.


Abstract

• To evaluate the efficacy and otologic effects of recombinant interferon beta serine for experimental rhinovirus colds, 38 healthy adults received nasal drops of recombinant interferon beta serine, 12x106 U, or placebo three times daily for 4.3 days beginning 36 hours after infection. Illness rates and severity did not differ between the groups, but the frequency of virus shedding was reduced on the fourth (37% vs 74%) and sixth (11% vs 42%) postchallenge days in recipients of recombinant interferon beta serine. Abnormal eustachian tube function in at least one ear was identified by the inflation-deflation test during 44% of observations in 13 infected recipients of recombinant interferon beta serine compared with 62% of observations in five placebo recipients. Tympanometry revealed middle-ear pressure abnormalities (<–50 or >20 mm H2O) in at least one ear during 18% of observations in recipients of recombinant interferon beta serine compared with 38% of observations in placebo recipients. These results suggest that antiviral therapy may alter the course of middle-ear dysfunction associated with experimental colds.

(Arch Otolaryngol Head Neck Surg. 1992;118:933-936)



Author Affiliations

From the Departments of Internal Medicine (Drs Sperber and Hayden), and Pathology (Dr Hayden), University of Virginia School of Medicine, Charlottesville; Department of Otolaryngology, University of Pittsburgh (Pa) School of Medicine, (Drs Doyle and McBride); and Richardson-Vicks Research Center, Shelton, Conn (Drs Sorrentino and Riker). Dr Sperber is presently with the Infectious Diseases Section, Department of Medicine, Hackensack (NJ) Medical Center. Dr McBride is presently with the Department of Otolaryngology, Georgetown Medical Center, Washington, DC.


Footnotes

Accepted for publication May 6, 1992.

Reprint requests to Department of Medicine, Box 473, University of Virginia Health Sciences Center, Charlottesville, VA 22908 (Dr Hayden).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.